title: Comparison of the western blot assay with the neutralizing-antibody and enzyme-linked immunosorbent assays for measuring antibody to verocytotoxin 1.
abstract: A Western blot (immunoblot) assay (WBA) was developed to detect immunoglobulin G (IgG) antibodies against Escherichia coli Verocytotoxin 1 (VT1) by using a chemiluminescence detection system. The assay was compared with a VT1-neutralizing-antibody (VT1-NAb) assay and an anti-VT1 IgG enzyme-linked immunosorbent assay (ELISA). When four human serum samples that were known to be positive by VT1-NAb assay and ELISA were titrated to the endpoint by the three assays, the WBA gave endpoint titers that were up to 8-fold higher than those by ELISA and up to 256-fold higher than those by the VT1-NAb assay. Of 32 serum samples that were known to be positive by VT1-NAb assay and ELISA, 31 (97%) were positive by WBA; the one sample with a discrepant result gave borderline results by the VT1-NAb assay and ELISA. Of 52 serum samples that were known to be negative by the VT1-NAb assay and ELISA, 50 (96%) were negative and 2 (4%) were positive by WBA. Of 44 serum samples that gave discrepant results by the VT1-NAb assay and ELISA, neither of the latter correlated with the results of WBA. In an investigation of 19 pairs of acute- and convalescent-phase serum samples from patients with hemolytic-uremic syndrome, 10 pairs that were positive by the VT1-NAb assay were also WBA positive, while 9 pairs that were NAb negative were also WBA negative. The WBA is inherently more specific and sensitive than either the NAb assay or the ELISA and may be used as a "gold standard" to detect IgG antibodies to VT1. Like the NAb assay and the ELISA for detecting antibodies to VT1, the WBA has little to offer in the diagnostic setting but is expected to play an important role in seroepidemiological studies.
authors.affiliation: Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.
authors.forename: D
authors.initials: D
authors.lastname: Reymond
authors.forename: M A
authors.initials: MA
authors.lastname: Karmali
authors.forename: I
authors.initials: I
authors.lastname: Clarke
authors.forename: M
authors.initials: M
authors.lastname: Winkler
authors.forename: M
authors.initials: M
authors.lastname: Petric
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis* / Q000097:blood; D001427:Bacterial Toxins / Q000276:immunology*; D015153:Blotting, Western / Q000379:methods* / Q000706:statistics & numerical data; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods* / Q000706:statistics & numerical data; D004926:Escherichia coli / Q000276:immunology; D004927:Escherichia coli Infections / Q000175:diagnosis / Q000276:immunology; D005069:Evaluation Studies as Topic; D006463:Hemolytic-Uremic Syndrome / Q000175:diagnosis / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis / Q000097:blood; D009500:Neutralization Tests / Q000379:methods* / Q000706:statistics & numerical data; D011817:Rabbits; D012680:Sensitivity and Specificity; D022622:Shiga Toxin 1
chemical_list: D000907:Antibodies, Bacterial; D001427:Bacterial Toxins; D007074:Immunoglobulin G; D022622:Shiga Toxin 1